NAD+ Optimization: NMN vs NR — The Complete Guide

Why NAD+ Matters

Nicotinamide adenine dinucleotide (NAD+) is not a supplement. It's a molecule your body already makes — one that sits at the center of cellular energy production, DNA repair, and gene expression regulation. Without it, your mitochondria can't produce ATP. Your sirtuins can't regulate gene silencing. Your PARP enzymes can't repair DNA damage.

Every cell in your body requires NAD+ to function. And every cell in your body is making less of it than it did a decade ago.

The decline is measurable. Studies show NAD+ levels in human tissue drop approximately 50% between ages 40 and 60 compared to younger adults. This isn't a theory — it's been quantified in skin, liver, brain, and blood samples. The question that launched an entire supplement category: if you could restore those levels, would you restore the cellular function that went with them?

Why NAD+ Declines: It's Not Just Wear and Tear

NAD+ depletion isn't passive degradation. It's active destruction. Three mechanisms drive the decline, and understanding them changes how you approach supplementation.

1. CD38: The NAD+ Destroyer

CD38 is an enzyme expressed on immune cells that consumes NAD+ as a substrate. A 2016 study in Cell Metabolism by Camacho-Pereira et al. demonstrated that CD38 expression increases dramatically with age, and this single enzyme is the primary driver of age-related NAD+ decline.

The mechanism is direct: CD38 degrades NAD+ into nicotinamide and ADP-ribose. As inflammatory signaling increases with age (inflammaging), CD38 expression rises, and NAD+ is destroyed faster than it can be synthesized. This creates a vicious cycle — lower NAD+ impairs sirtuin function, which increases inflammatory signaling, which drives more CD38 expression, which destroys more NAD+.

This has a direct implication for supplementation: NMN is a substrate for CD38. CD38 degrades NMN directly. NR, by contrast, has been shown to inhibit CD38 activity. This is one of the mechanistic arguments in NR's favor — it's not just supplying more precursor, it's also slowing the destruction of the NAD+ you already have.

2. PARP Activation

Poly(ADP-ribose) polymerases (PARPs) are DNA repair enzymes that consume NAD+ as fuel. As DNA damage accumulates with age — from UV, oxidative stress, replication errors — PARPs work harder and consume more NAD+. PARP1 alone can deplete a cell's entire NAD+ pool during intensive DNA repair events.

This isn't a malfunction. PARPs are doing their job. The problem is that chronic DNA damage in aging tissues keeps PARPs constitutively active, creating a sustained drain on NAD+ that the biosynthetic machinery can't keep up with.

3. Declining Biosynthesis

The salvage pathway — the primary route for recycling NAD+ — becomes less efficient with age. NAMPT, the rate-limiting enzyme in this pathway, shows reduced expression and activity in aged tissues. So you're making less NAD+, while simultaneously destroying it faster. The math only goes one direction.

What NAD+ Actually Does: The Three Systems

Sirtuins: The Longevity Regulators

Sirtuins (SIRT1-7) are a family of NAD+-dependent deacetylases that regulate gene expression, DNA repair, mitochondrial function, and stress response. They can only function when NAD+ is available — it's a required cofactor, not just fuel.

SIRT1 and SIRT3 are the most studied in aging. SIRT1 regulates hundreds of genes involved in inflammation, metabolism, and stress resistance. SIRT3 maintains mitochondrial function and prevents oxidative damage. When NAD+ drops, sirtuin activity drops with it — regardless of how much sirtuin protein is present. It's like having an engine with no gasoline.

PARPs: DNA Damage Response

As described above, PARPs use NAD+ to repair DNA breaks. Adequate NAD+ ensures that damage is repaired promptly before it accumulates into mutations or triggers cellular senescence. NAD+ depletion forces a triage: not all damage gets repaired, and the unrepaired damage compounds over time.

CD38 and Immune Signaling

NAD+ is also a signaling molecule in immune function. CD38's role isn't purely destructive — it generates calcium-mobilizing second messengers that regulate immune cell activation. The problem is one of proportion: in aging, CD38's NAD+ consumption outpaces any signaling benefit.

NMN vs NR: The Head-to-Head Data

For years, the NMN vs NR debate was theoretical — advocates on each side cited mechanism and animal data because no human trial had directly compared them. That changed in 2026 with two landmark studies.

Study 1: Nestlé Trial (Nature Metabolism, 2026)

Results: Both NR and NMN approximately doubled circulating NAD+ levels. NR produced a slightly larger increase (+49.4 µM vs. +43.1 µM above placebo) — roughly 15% more — but the difference was not statistically significant. Nicotinamide showed no chronic NAD+ elevation, only a transient 4-hour spike.

The critical finding: NR and NMN both work. At equivalent doses, they produce comparable NAD+ increases. The NR vs NMN debate, at least on the metric of blood NAD+ elevation, is largely settled — they're in the same ballpark.

Study 2: Berven et al. (iScience, 2026)

Results: NR increased blood NAD+ by 161% (27 → 70.5 µM). NMN increased it by 69% (32 → 53.7 µM). NR produced approximately 2.3 times the NAD+ increase of NMN at the same dose.

The more significant finding: NR increased brain NAD+ levels after 4 weeks of supplementation — one of the first studies to demonstrate that an oral NAD+ precursor crosses the blood-brain barrier in humans. This has implications for neurodegeneration and cognitive aging that blood NAD+ alone can't address.

The Uncomfortable Truth About NMN's Mechanism

Here's something NMN supplement companies don't advertise: NMN must be converted to NR before it can enter cells. NMN is too large to cross cell membranes through the standard nucleoside transporters. The dominant pathway, confirmed in multiple studies, is that gut bacteria convert NMN to nicotinic acid (a form of niacin), which is then absorbed and converted back to NAD+ in the liver via the Preiss-Handler pathway.

NR, on the other hand, enters cells directly through equilibrative nucleoside transporters. It's one step closer to NAD+ in the biosynthetic pathway and doesn't require bacterial conversion.

This doesn't mean NMN doesn't work — 30+ human trials confirm it raises NAD+. But it does mean the marketing narrative of "NMN is one step closer to NAD+ so it's better" is biochemically backward. The cellular entry route matters more than the position on a pathway diagram.

The Human Trial Evidence Base

The combined clinical data across both precursors is now substantial. Here's what the trials consistently show:

What's Established

• Both NMN and NR reliably raise blood NAD+ levels in humans. Effect size: typically 40–100% increase above baseline at standard doses (250–1,000 mg/day). Plateaus within 2–4 weeks.
• Safety profile is clean. Across 30+ trials spanning doses from 100 mg to 2,000 mg daily and durations up to 24 weeks, no serious adverse events have been attributed to either compound. NMN has been tested up to 1,250 mg/day with no safety signals.
• Functional improvements observed (but modest): Walking speed in older adults (NMN 250 mg, 12 weeks), grip strength (NMN 250 mg, 12 weeks), aerobic capacity in middle-aged runners (NMN 600–1,200 mg, 6 weeks), sleep quality (NMN 250 mg, 12 weeks), blood pressure reduction (~4–6 mmHg systolic in adults over 60).

What's Not Established

• Lifespan extension in humans — no trial has been designed or powered for this outcome
• Definitive superiority of one precursor over the other — the two head-to-head trials lean toward NR, but methodological differences prevent a clean conclusion
• Optimal dose — responses vary dramatically between individuals. One trial (2023) found that some participants simply didn't respond to NMN at all, while others showed robust NAD+ increases at the same dose
• Long-term outcomes — the longest trial is 24 weeks. What happens at 2 years? 5 years? Unknown.

Dosing Protocols

The David Sinclair Protocol (For Context)

Harvard geneticist David Sinclair has publicly disclosed taking 1,000 mg NMN daily (sublingual, morning) alongside 1,000 mg resveratrol with yogurt. This is widely cited in the biohacking community but represents one researcher's personal protocol, not a clinical recommendation. Sinclair's own research focuses on NMN, and he has financial ties to NMN-related ventures. This is context, not a reason to dismiss his work — but it's context you should have.

What to Stack With NAD+ Precursors

NAD+ precursors address the supply side of the equation. The most rational stack addresses both supply and demand:

How to Measure Whether It's Working

If you're investing in NAD+ supplementation, measure the outcome. Otherwise you're taking an expensive supplement on faith.

NMN Regulatory Status

In November 2022, the FDA declared that NMN could not be sold as a dietary supplement because it was being investigated as a new drug (by Metro International Biotech, which had an IND filing for MIB-626). This created regulatory chaos — NMN was pulled from Amazon in the US and major retailers complied with the FDA's position.

As of 2026, NMN remains available through many direct-to-consumer supplement companies, but its legal status as a dietary supplement in the US is contested. NR (sold as Niagen/Tru Niagen) has GRAS status and is not affected by this regulatory issue.

This doesn't mean NMN is unsafe or ineffective. It means that the regulatory environment adds a layer of sourcing risk — companies selling NMN in the current gray zone may not be subject to the same manufacturing standards as those selling NR. Third-party testing (COA verification) is even more important for NMN purchases.

The Verdict: NMN or NR?

The honest answer, based on the 2026 data:

If you're choosing one: The current evidence leans toward NR. It produces equal or greater NAD+ increases at equivalent doses, enters cells directly without requiring bacterial conversion, inhibits rather than feeds CD38, has demonstrated brain NAD+ penetration in humans, and has cleaner regulatory status. The Berven crossover trial — the most rigorous head-to-head design — showed NR producing 2.3x the NAD+ increase of NMN at the same dose.

If you're already on NMN and it's working: The evidence doesn't say NMN is bad. 30+ human trials show it safely raises NAD+, with functional improvements in mobility, sleep, endurance, and metabolic markers. If your NAD+ levels are confirmed elevated and you're seeing benefits, switching for a marginal advantage is a judgment call, not a mandate.

What actually matters more than which precursor: Whether you're measuring the outcome. Taking either one blind and hoping for the best is a waste of money. Test your NAD+ levels. If they're not going up, change something. If they are going up but nothing else is improving, the bottleneck is somewhere else — and pouring more precursor into the system won't fix it.

NAD+ decline is real, measurable, and mechanistically linked to aging. The tools to address it exist. The proof that addressing it extends human healthspan or lifespan is still incomplete. Optimize, measure, adjust.